Higher BMI associated with cancer risk, with or without another underlying condition

Publicly released:
International
Photo by i yunmai on Unsplash
Photo by i yunmai on Unsplash

People with higher BMIs are over 10% more likely to develop obesity-related cancers such as colorectal, kidney, pancreatic or ovarian cancer even if they don't have a cardiometabolic condition such as heart disease or type 2 diabetes. The researchers used data from nearly 600,000 people in the UK to investigate how cardiometabolic conditions interact with higher BMI - a metric used as an approximate measure of overweight/obesity - and cancer risk. They say for those without a cardiometabolic disorder, a five-point increase in BMI score was associated with an 11% increased of obesity-related cancers. They say the risk is especially high for those who are obese and have heart disease, so weight loss could be especially important for this group to reduce cancer risk.

Media release

From: Springer Nature

Health: Higher BMI associated with increased cancer risk with or without cardiometabolic disease

People with higher BMIs are more than ten percent more likely to develop cancers such as colorectal, kidney, pancreatic or ovarian cancer, regardless of whether they have a cardiometabolic disorder (cardiovascular disease or type 2 diabetes) or not, reports a paper published in BMC Medicine. The findings, based on a sample of over 500,000 European adults, also suggest that having cardiovascular disease alongside a higher BMI is associated with an even greater risk of cancer, highlighting the need for obesity prevention to reduce cancer risk in these groups.

A BMI of more than 25 is an established risk factor for at least thirteen types of cancer, including breast cancer in postmenopausal women, colorectal, liver, kidney, pancreatic and ovarian cancers. However, it is not clear whether high BMI alone is associated with increased risk, or whether the presence of other obesity-related conditions such as cardiovascular disease and type 2 diabetes my play a part.

Heinz Freisling and colleagues used data from a total of 577,343 adults from the UK Biobank (344,094 participants) and European Prospective Investigation into Cancer and nutrition (EPIC) (233,249 participants) study cohorts to investigate the association between BMI and cancer in adults with or without cardiometabolic diseases. Follow-up from recruitment was a median of 10.9 years for both cohorts, and 32,549 (9.5%) participants in UK Biobank developed primary cancers, compared to 19,833 (8.3%) participants in the EPIC. 76,881 (22%) of UK Biobank participants were obese compared to 36,361 (15%) of EPIC participants.

In total, for individuals without a cardiometabolic disorder, a five-point increase in BMI score was associated with an 11 percent increased risk obesity-related cancers. A similar increased risk was observed among participants that did have a cardiometabolic disorder; those with type 2 diabetes saw an 11 percent increased risk per five-point increase in BMI score, while those with cardiovascular disease saw a 17 percent increase in risk.

The results demonstrate the increased cancer risk associated with increased BMI, regardless of whether the individual has other cardiometabolic conditions. However, obese individuals with cardiovascular disease appeared to be at particularly increased risk of cancer, suggesting that targeted intervention to lose weight could benefit this group.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Springer Nature, Web page The URL will go live after the embargo ends
Journal/
conference:
BMC Medicine
Research:Paper
Organisation/s: International Agency for Research On Cancer, France
Funder: Funding [grant number: IIG_2019_1978] was obtained from World Cancer Research Fund (UK), as part of the World Cancer Research Fund International grant program. The coordination of EPIC is financially supported by the International Agency for Research on Cancer (IARC) and by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are supported by: Danish Cancer Society (Denmark); German Cancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk; MR/M012190/1 to EPIC-Oxford). (United Kingdom). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Media Contact/s
Contact details are only visible to registered journalists.